Skip to main content
NCBI home page
Gastroenterology Research and Practice logoLink to Gastroenterology Research and Practice
. 2015 May 18;2015:141070. doi: 10.1155/2015/141070

Role of TLR4  rs4986790A>G and rs4986791C>T Polymorphisms in the Risk of Inflammatory Bowel Disease

Ran Ao 1,*, Ying Wang 1, Dao-Rong Zhnag 2, Ya-Qi Du 1
PMCID: PMC4451775  PMID: 26089865

Abstract

Objective. The present meta-analysis investigated the contribution of TLR4 rs4986790A>G and rs4986791C>T genetic polymorphisms in increasing the risk of inflammatory bowel disease (IBD). Methods. Databases were searched using a combination of keywords related to TLR4 and IBD. Relevant studies were selected based on strict inclusion and exclusion criteria. Meta-analysis of the data extracted from the selected studies was performed using CMA 2.0 statistical analysis software. Results. Out of the 70 studies retrieved by database search, only 13 studies were eligible for inclusion in this meta-analysis and these 13 studies contained a total number of 4409 IBD patients and 5693 healthy controls. The meta-analysis results demonstrated that TLR4 rs4986790A>G polymorphism is associated with an increased risk of IBD (allele model: OR = 1.268, 95% CI = 1.124~1.431, and P < 0.001; dominant model: OR = 1.240, 95% CI = 1.090~1.409, and P = 0.001). Similarly, TLR4 rs4986791C>T polymorphism also conferred an increased risk of IBD (allele model: OR = 1.259, 95% CI = 1.092~1.453, and P = 0.002; dominant model: OR = 1.246, 95% CI = 1.072~1.447, and P = 0.004). Conclusion. Our meta-analysis results demonstrate that TLR4 rs4986790A>G and rs4986791C>T genetic polymorphisms are associated with the etiopathogenesis of IBD.

1. Introduction

Inflammatory bowel disease (IBD) mainly consists of two types, Crohn's disease (CD) and ulcerative colitis (UC), both of which are chronic inflammatory disorders of unknown etiology [1]. Northern Europe and North America show high incidence rates of pediatric IBD [2]. In particular, UC and CD together affect approximately 1 in 250 among European, North American, and Australasian populations [3]. UC is characterized by inflammation of the colonic mucosa that spreads proximally from the anus, while, in CD, the inflammatory lesions may occur in any area of the gastrointestinal (GI) tract and involve the entire thickness of the intestinal wall, exhibiting focal characteristics [4, 5]. The etiopathogenesis of IBD is unknown, but genetic predisposition, gut microbial flora, and environmental factors are suspected to play important roles. For example, abnormal immune response by the host towards gut microbes is implicated in the pathogenesis of IBD. Similarly, environmental triggers, including nonsteroidal anti-inflammatory drugs, antibiotics, and bacterial and viral infections, are risk factors that enhance the severity of IBD [5–7]. Previous studies suggest a significant contribution of genetic factors to the etiology of IBD and an increased IBD risk is observed in individuals with a family history of IBD [2]. With recent advances in complementary technologies to uncover genetic risk factors for human diseases, more than 40 IBD susceptibility loci have been identified through linkage analysis, association mapping, and candidate gene association studies [5, 8]. Most importantly, imbalances in pro- and anti-inflammatory cytokine levels, resulting from the altered expression of genes involved in innate immunity, are implicated in the development and unremitted course of IBD [9].

Toll-like receptor 4 (TLR4) is important for host immune response to pathogens and has a specific role in inflammatory pathways [10]. TLR4 is also implicated in colitis-associated neoplasia and thus is intimately linked to IBD onset and progression. TLR4 (EMBL/GenBank/DDBJ accession number U93091) maps to chromosome 9q32-33 and is a member of an emerging family of molecules implicated in innate immune recognition [11]. TLR4 is the main receptor for lipopolysaccharide (LPS) expressed in macrophages, dendritic cells, endothelial cells, and the intestinal epithelium [12]. TLR4 mediates lipopolysaccharide-induced maturation and activation of myeloid dendritic cells [10]. Importantly, TLR4 signaling in immune cells of the colonic mucosa plays a central role in maintaining chronic inflammatory state by producing inflammatory cytokines [13]. Recent results from animal models show that tissue inflammation correlating with IL-17 production is mediated by TLR4 signaling in chronic inflammatory diseases [14]. Additionally, an imbalance in T cell subsets, such as T regulatory cells, Th1, Th2, and Th17, and the resulting altered profile of cytokine secretion from these cells, influences the susceptibility to IBD [15]. Consistent with this, an upregulation of TLR4 in the colonic mucosal epithelium and in myeloid dendritic cells is reported in active IBD [16]. Two single nucleotide polymorphisms (SNPs) in the TLR4 gene, D299G (299 A/G, Asp299Gly, and rs4986790A>G) and T399I (399 C/T, Thr399Ile, and rs4986791C>T), appear to be prominent in host interactions with the environment [15]. These functional TLR4 polymorphisms modulate innate host defense responses against infections and their frequency in various populations is thought to be influenced by selection pressures, which is dependent on the interactions with local pathogens [17]. A study carried out in a Caucasian population reported that TLR4 rs4986790A>G and rs4986791C>T SNPs conferred a high risk of developing IBD [12]. However, a study conducted in a Han population contradicted these findings and showed no significant association between TLR4 rs4986790A>G polymorphism and IBD susceptibility [18]. Therefore, the present meta-analysis was conducted to examine the association between the two TLR4 polymorphisms, rs4986790A>G and rs4986791C>T, and IBD susceptibility.

2. Methods and Materials

2.1. Literature Search

PubMed, EBSCO, Ovid, Springerlink, Wiley, Web of Science, Wanfang databases, China National Knowledge Infrastructure (CNKI), and VIP databases were searched to identify relevant studies published prior to October 2014. Manual search of cross-references was also conducted to identify additional studies. The search involved a combination of keywords and free words related to inflammatory bowel disease (IBD), ulcerative colitis (UC), Crohn's disease (CD), and TLR4 using a highly efficient and sensitive searching strategy: (“Inflammatory Bowel Diseases” or “Colitis, Ulcerative” or “Crohn Disease”) and (“Toll-Like Receptor 4” or “TLR-4” or “TLR 4”) and (“Polymorphism, Genetic” or “SNP”). Database search was restricted to studies published in Chinese and English languages.

2.2. Inclusion and Exclusion Criteria

The inclusion criteria for selection of studies for this meta-analysis were as follows: (1) studies should be related to IBD risk and TLR4 gene polymorphisms rs4986790A>G and rs4986791C>T; (2) study design should be case-control study; (3) subjects in the enrolled studies should be patients with confirmed IBD diagnosis and healthy subjects as controls; (4) outcome index is as follows: allele and genotype frequencies in case and control groups; (5) only studies published in Chinese and English languages were selected. The exclusion criteria were as follows: (1) summary and abstracts were not selected; (2) animals studies were excluded; (3) duplicate publications were not used; (4) studies that provided insufficient information were not used; (5) for overlapping publications, only the most recent or the most complete study was included in this meta-analysis.

2.3. Data Extraction and Quality Assessment

Data was extracted from each study by two independent investigators and the following information was collected: surname and initials of the first author, year of submission, country, ethnicity, language, age, gender, cases, detective methods, research designs, and single nucleotide polymorphism (SNP). Disagreement on the inclusion of any study was resolved by consultation with a third investigator.

2.4. Statistical Analysis

Comprehensive Meta-Analysis 2.0 software (Biostatic Inc., Englewood, New Jersey, USA) was used for statistical analysis of the extracted data. The differences in allele and genotype frequencies of TLR4 rs4986790A>G and rs4986791C>T polymorphisms were compared using odds ratio (OR) and its 95% confidence intervals (95% CI). Z test was carried out to evaluate the significance of overall effect values [19]. Forest plots were analyzed to compare ORs and 95% CI between case and control groups. The heterogeneity between the studies was evaluated with Cochran's Q-statistic (P < 0.05 was considered significant) and I 2 test (0%: no heterogeneity; 100%: maximal heterogeneity) [19, 20]. In order to calculate the pooled ORs, fixed or random effects models were used. When significant heterogeneity was observed (P < 0.05 or I 2 > 50%), a fixed effects model was used; otherwise, the random effects model was employed [21]. Univariate and multivariate metaregression analysis of outcomes were utilized to identify potential sources of heterogeneity and Monte Carlo simulation was employed for further confirmation [22–24]. Sensitivity analysis was performed to evaluate whether removal of any single study influenced the overall outcomes. The funnel plot, classic fail-safe N, and Egger's linear regression test were used to assess publication bias to ensure the reliability of the results [25–27]. A bilateral test was conducted, with P < 0.05 considered to be significant.

3. Results

3.1. Selection of Eligible Studies

Electronic database and manual searches resulted in the identification of 70 potential articles. After excluding duplicates (n = 9), nonhuman studies (n = 2), letters, reviews, non-English or non-Chinese studies (n = 3), studies that were not case-control design (n = 13), and studies unrelated to our research topic (n = 22), a total of 17 studies remained for full-text review. Following the inclusion and exclusion criteria, 1 study without statistics and 3 studies with insufficient statistics were eliminated. Finally, 13 studies [10, 15, 16, 28–37] published between 2004 and 2013 were included in the current meta-analysis and contained 4409 IBD patients (1997 UC patients and 2412 CD patients) and 5693 healthy controls. Of these, 10 studies were conducted in Caucasian population and 3 studies were in Asian population. Two major TLR4 SNPs, rs4986790A>G and rs4986791C>T, were involved in the meta-analysis (Figure 1). Table 1 shows the minimum minor allele frequency (MAF) of the SNPs in different ethnic groups from HapMap, which illustrates the pattern of MAFs in major ethnic groups. SNP detection methods in the 13 studies were polymerase chain reaction with the restriction fragment length polymorphism (PCR-RFLP), allele-specific polymerase chain reaction (AS-PCR), and TaqMan assay. Baseline characteristics of the 13 eligible studies are summarized in Table 2.

Figure 1.

Figure 1

Open in a new tab

Schematic diagram of the position of TLR4 gene (rs4986790A>G and rs4986791C>T).

Table 1.

MAF of the SNPs in different ethnic groups from the HapMap population.

Ethnicity rs4986790A>G rs4986791C>T
CEU    
 Alleles A:G C:T
 MAF 0.033 0.033
CHB    
 Alleles A:A C:C
 MAF 0 0
YRI    
 Alleles A:G C:C
 MAF 0.033 0
JPT    
 Alleles A:A C:C
 MAF 0 0
JPT + CHB    
 Alleles A:A C:C
 MAF 0 0
Open in a new tab

CEU: 30 trios of Utah residents of Northern and Western European ancestry; CHB: 45 unrelated Han Chinese individuals from Beijing, China; YRI: 30 adult-and-both-parents Yoruba trios from Ibadan, Nigeria; JPT: 44 unrelated Japanese individuals from Tokyo, Japan; JPT + CHB: combined panel of Japanese in Tokyo, Japan, and Han Chinese in Beijing, China; MAF: minimum minor allele frequency; SNP: single nucleotide polymorphism.

Table 2.

Baseline characteristics of included studies.

First author Year Country Ethnicity Total Sample size Gender (M/F) Age (years) Genotyping methods SNP
Case Control Case Control Case Control
Mohammadia [15] 2013 Iran Asians 341 85 256 38/47 136/120 38 ± 16 37 ± 12 PCR-RFLP S1 & S2
Meenaa [28] 2013 India Asians 400 199 201 122/77 118/83 34.9 ± 11.6 36.4 ± 14.1 PCR-RFLP S1 & S2
Meenab [28] 2013 India Asians 247 46 201 25/21 118/83 32.58 ± 11.05 36.4 ± 14.1 PCR-RFLP S1 & S2
Sivarama [10] 2012 India Asians 315 139 176 187/128 40.97 ± 14.11 (18–80) AS-PCR S1
Magalhäes Queiroza [29] 2009 Brazil Caucasians 583 42 541 6/36 409/132 38.93 ± 14.73 33.87 ± 9.96 PCR-RFLP S1
Magalhäes Queirozb [29] 2009 Brazil Caucasians 584 43 541 20/23 409/132 40.88 ± 14.16 33.87 ± 9.96 PCR-RFLP S1
Rigolia [30] 2008 Italy Caucasians 148 45 103 27/18 68/35 43.2 ± 11.0 46.6 ± 9.8 PCR-RFLP S1 & S2
Rigolib [30] 2008 Italy Caucasians 236 133 103 70/63 68/35 43.5 ± 10.7 46.6 ± 9.8 PCR-RFLP S1 & S2
Lappalainena [31] 2008 Finland Caucasians 649 459 190 NR NR PCR-RFLP S1 & S2
Lappalainenb [31] 2008 Finland Caucasians 430 240 190 NR NR PCR-RFLP S1 & S2
Hongb [32] 2007 New Zealand Caucasians 370 182 188 NR NR PCR-RFLP S1 & S2
Browninga [33] 2007 New Zealand Caucasians 821 405 416 53/214 240/176 NR TaqMan assay S1 & S2
Browningb [33] 2007 New Zealand Caucasians 805 389 416 64/250 240/176 NR TaqMan assay S1 & S2
Baumgarta [16] 2007 Germany Caucasians 548 145 403 67/78 NR 31 ± 13.6 NR PCR-RFLP S1
Baumgartb [16] 2007 Germany Caucasians 638 235 403 90/145 NR 26 ± 10.3 NR PCR-RFLP S1
Oostenbruga [34] 2005 Netherlands Caucasians 516 217 299 NR NR PCR-RFLP S1 & S2
Oostenbrugb [34] 2005 Netherlands Caucasians 803 504 299 NR NR PCR-RFLP S1 & S2
Brandb [35] 2005 Germany Caucasians 403 204 199 96/108 99/100 37.8 ± 11.8 46.4 ± 15.3 AS-PCR S1 & S2
Töröka [36] 2004 Germany Caucasians 243 98 145 45/53 71/74 42.7 ± 13.3 44.6 ± 12.5 PCR-RFLP S1 & S2
Törökb [36] 2004 Germany Caucasians 247 102 145 37/65 71/74 40.9 ± 13.7 44.6 ± 12.5 PCR-RFLP S1 & S2
Franchimonta [37] 2004 Belgium Caucasians 302 163 139 85/78 NR 29.78 ± 12.8 NR PCR-RFLP S1
Franchimontb [37] 2004 Belgium Caucasians 473 334 139 136/198 NR 26.6 ± 10.3 NR PCR-RFLP S1
Open in a new tab

M: male; F: female; SNP: single nucleotide polymorphism; aulcerative colitis; bCrohn's disease; NR: not reported; PCR-RFLP: polymerase chain reaction-restriction fragment length polymorphism; AS-PCR: allele-specific polymerase chain reaction; S1: rs4986790A>G; S2: rs4986791C>T.

3.2. Meta-Analysis of the Association between TLR4 Gene rs4986790A>G Polymorphism and IBD Risk

Thirteen studies investigated the association between TLR4 gene rs4986790A>G polymorphism and IBD risk. No heterogeneity was observed in this meta-analysis (allele model: I 2 = 26.058%, P h = 0.129; dominant gene model: I 2 = 27.761%, P h = 0.112), and thus fixed effects model was adopted. Our findings demonstrated that TLR4 rs4986790A>G polymorphism significantly increased IBD risk (allele model: OR = 1.268, 95% CI = 1.124~1.431, and P < 0.001; dominant gene model: OR = 1.240, 95% CI = 1.090~1.409, and P = 0.001) (Figures 2(a) and 2(b) and Table 2). Subgroup analysis based on ethnicity demonstrated that rs4986790A>G increased the IBD risk in Caucasians (allele model: OR = 1.273, 95% CI = 1.114~1.456, and P < 0.001; dominant model: OR = 1.272, 95% CI = 1.105~1.466, and P = 0.001); but this relationship was not found in Asian population (allele model: OR = 1.246, 95% CI = 0.945~1.642, and P = 0.119; dominant model: OR = 1.099, 95% CI = 0.812~1.489, and P = 0.540) (Figures 3(a) and 3(b)). Subgroup analysis based on IBD types suggested that the TLR4 rs4986790A>G polymorphism conferred an increased risk of both UC and CD (CD: allele model: OR = 1.242, 95% CI = 1.053~1.489, and P = 0.011; dominant model: OR = 1.247, 95% CI = 1.039~1.497, and P = 0.018; UC: allele model: OR = 1.283, 95% CI = 1.085~1.518, and P = 0.004; dominant model: OR = 1.233, 95% CI = 1.030~1.475, and P = 0.023) (Figures 3(c) and 3(d)).

Figure 2.

Figure 2

Open in a new tab

Forest analyses of the differences in allele and genotype frequencies of TLR4 rs4986790A>G and rs4986791C>T polymorphism between case and control groups. (a) Forest analyses of the differences in allele frequencies of rs4986790A>G. (b) Forest analyses of the differences in genotype frequencies of rs4986790A>G. (c) Forest analyses of the differences in allele frequencies of rs4986791C>T. (d) Forest analyses of the differences in genotype frequencies of rs4986791C>T.

Figure 3.

Figure 3

Open in a new tab

Subgroup analysis of the differences in allele and genotype frequencies of TLR4 rs4986790A>G and rs4986791C>T polymorphism between case and control groups. (a) Ethnicity analysis of the differences in allele frequencies of TLR4 rs4986790A>G; (b) disease analysis of the differences in allele frequencies of TLR4 rs4986790A>G; (c) ethnicity analysis of the differences in genotype frequencies of TLR4 rs4986790A>G; (d) disease analysis of the differences in genotype frequencies of TLR4 rs4986790A>G; (e) ethnicity analysis of the differences in allele frequencies of TLR4 rs4986791C>T; (f) disease analysis of the differences in allele frequencies of TLR4 rs4986791C>T; (g) ethnicity analysis of the differences in genotype frequencies of TLR4 rs4986791C>T; (h) disease analysis of the differences in genotype frequencies of TLR4 rs4986791C>T.

3.3. Meta-Analysis of the Association between TLR4 Gene rs4986791C>T Polymorphism and IBD Risk

Nine studies investigated the association between TLR4 rs4986791C>T polymorphism and IBD risk. No heterogeneity was observed in this meta-analysis (allele model: I 2 = 44.929%, P h = 0.031; dominant gene model: I 2 = 33.948%, P h = 0.097), and thus fixed effects model was adopted. The meta-analysis results showed that rs4986791C>T significantly increased IBD risk (allele model: OR = 1.259, 95% CI = 1.092~1.453, and P = 0.002; dominant gene model: OR = 1.246, 95% CI = 1.072~1.447, and P = 0.004) (Figures 2(c) and 2(d) and Table 3). Subgroup analysis based on ethnicity demonstrated that TLR4 polymorphism rs4986791C>T was associated with an increased risk of IBD risk in both Asian and Caucasian populations (Asians: allele model: OR = 1.608, 95% CI = 1.080~2.395, and P = 0.019; dominant model: OR = 1.517, 95% CI = 1.000~2.303, and P = 0.050; Caucasians: allele model: OR = 1.215, 95% CI = 1.042~1.415, and P = 0.013; dominant model: OR = 1.210, 95% CI = 1.030~1.421, and P = 0.020) (Figures 3(e) and 3(f)). Interestingly, subgroup analysis based on the diseases type suggested that TLR4 polymorphism rs4986791C>T conferred an increased risk of UC (allele model: OR = 1.304, 95% CI = 1.060~1.604, and P = 0.012; dominant model: OR = 1.276, 95% CI = 1.026~1.588, and P = 0.028), but CD did not exhibit such an association with TLR4 polymorphism rs4986791C>T (allele model: OR = 1.220, 95% CI = 0.998~1.486, and P = 0.058; dominant model: OR = 1.219, 95% CI = 0.991~1.499, and P = 0.061) (Figures 3(g) and 3(h)).

Table 3.

Comparisons of genotype and allele frequencies between the case and the control groups.

Gene model   rs4986790A>G rs4986791C>T
OR 95% CI P OR 95% CI P
M allele versus W allele (allele model) Overall 1.268 1.124~1.431 <0.001 1.259 1.092~1.453 0.002
Ethnicity            
 Asians 1.246 0.945~1.642 0.119 1.608 1.080~2.395 0.019
 Caucasians 1.273 1.114~1.456 <0.001 1.215 1.042~1.415 0.013
Disease            
 CD 1.242 1.053~1.489 0.011 1.220 0.998~1.486 0.058
 UC 1.283 1.085~1.518 0.004 1.304 1.060~1.604 0.012
WM + MM versus WW (dominant model) Overall 1.240 1.090~1.409 0.001 1.246 1.072~1.447 0.004
Ethnicity            
 Asians 1.099 0.812~1.489 0.540 1.517 1.000~2.303 0.050
 Caucasians 1.272 1.105~1.466 0.001 1.210 1.030~1.421 0.020
Disease            
 CD 1.247 1.039~1.497 0.018 1.219 0.991~1.499 0.061
 UC 1.233 1.030~1.475 0.023 1.276 1.026~1.588 0.028
MM versus WW (homozygous model) Overall 2.438 1.413~4.204 0.001 1.933 0.971~3.850 0.061
WM versus MM (heterozygous model) Overall 0.477 0.272~0.836 0.010 0.625 0.308~1.268 0.193
MM versus WW + WM (recessive model) Overall 3.211 1.840~5.606 <0.001 1.891 0.950~3.764 0.070
Open in a new tab

OR: odds ratio; 95% CI: 95% confidential intervals; UC: ulcerative colitis; CD: Crohn's disease.

3.4. Potential Sources of Heterogeneity

Sensitivity analysis demonstrated that no single study had a significant effect on pooled ORs of the association of TLR4 rs4986790A>G and TLR4 rs4986791C>T polymorphisms with IBD susceptibility (Figure 4). The univariate meta-regression analysis showed that none of sample size, ethnicity, disease and SNP were main sources of heterogeneity and key factors for influencing overall effect size (all P > 0.05) (Figure 5). The multivariate metaregression analysis also identified that sample size, ethnicity, disease and SNP were not the potential sources of heterogeneity (all P > 0.05) (Table 4). The shape of the funnel plots did not reveal asymmetry and the statistical results did not indicate publication bias. Classic fail-safe N and Egger's linear regression test further confirmed the lack of significant publication bias (all P > 0.05) (Figure 6).

Figure 4.

Figure 4

Open in a new tab

Sensitivity analysis of the differences in allele and genotype frequencies of TLR4 rs4986790A>G and rs4986791C>T polymorphism between case and control groups. (a) Sensitivity analysis of the differences in allele frequencies of rs4986790A>G; (b) sensitivity analysis of the differences in genotype frequencies of rs4986790A>G; (c) sensitivity analysis of the differences in allele frequencies of rs4986791C>T; (d) sensitivity analysis of the differences in genotype frequencies of rs4986791C>T.

Figure 5.

Figure 5

Open in a new tab

Metaregression analyses for potential source of heterogeneities on comparison of differences in allele and genotype frequencies of TLR4 rs4986790A>G and rs4986791C>T polymorphisms between case and control groups. (a) Metaregression analysis on sample size between case and control groups. (b) Metaregression analysis on ethnicity between case and control groups. (c) Metaregression analysis on disease between case and control groups. (d) Metaregression analysis on SNP between case and control groups.

Table 4.

Metaregression analyses of potential source of heterogeneity.

Heterogeneity factors Coefficient SE t P (adjusted) 95% CI
LL UL
Sample size −0.001 0.001 −1.93 0.066 −0.001 0.001
Ethnicity 0.223 0.184 1.21 0.232 −0.152 0.598
Disease −0.135 0.129 −1.05 0.325 −0.398 0.127
SNP 0.037 0.126 0.29 0.764 −0.219 0.293
Open in a new tab

SE: standard error; LL: lower limit; UL: upper limit; SNP: single nucleotide polymorphism.

Figure 6.

Figure 6

Open in a new tab

Publication bias of the differences in allele and genotype frequencies of TLR4 rs4986790A>G and rs4986791C>T polymorphism between case and control groups. (a) Publication bias of the differences in allele frequencies of rs4986790A>G; (b) publication bias of the differences in genotype frequencies of rs4986790A>G; (c) publication bias of the differences in allele frequencies of rs4986791C>T; (d) publication bias of the differences in genotype frequencies of rs4986791C>T.

4. Discussion

In this study, the meta-analyses results showed that TLR4 polymorphisms rs4986790A>G and rs4986791C>T were associated with an increased susceptibility to IBD, implying that these SNPs are significant genetic risk factors for IBD. TLR4 is one of the key mediators of host immune responses towards bacteria and viruses [38]. Single nucleotide polymorphisms in TLR4 can lead to abnormal signaling by altering the ligand binding of TLR4 and create an imbalance between pro- and anti-inflammatory cytokine secretion, resulting in the risk of chronic inflammation [39]. Functional TLR4 gene polymorphisms create variations in the receptor domain responsible for recognition of pathogen-associated molecular pattern and, thereby, modulate immune response towards Th1 phenotype [28]. In addition, polymorphisms in other genes that are expressed in antigen-presenting cells, such as CD4, may also cause an inappropriate activation and polarization of T cells, as well as activating nuclear factor kappa B (NF-κB), a key transcription factor related to inflammation [16].

TLR4 SNPs show unique distribution patterns in different populations from Africa, Asia, and Europe, and malarial infection is proposed as an explanation for these differences [40]. For example, Ioana et al. showed a mixed intermediate pattern of TLR4 SNPs in Iranian population compared to the commonly found patterns in the Americas, Europe, Africa, and Eastern Asia, which suggests the absence or weakness of selection pressure influencing TLR4 polymorphisms in this population [17]. In this context, two important SNPs in TLR4 gene used in this study, rs4986790A>G and rs4986791C>T, alter the response of TLR4 receptor to LPS [12]. The interaction between LPS and TLR4 is a multistep process that LPS is present in circulation as a bound form with lipopolysaccharide-binding protein, which acts as an opsonin for CD14. CD14 subsequently catalyzes the binding of LPS to myeloid differentiation protein-2 (MD-2) and this allows LPS to be transferred to MD-2 and further facilitate a direct interaction with TLR4 to form a new LPS/MD-2/TLR4 complex [41]. TLR4 is expressed in macrophages, dendritic cells, and endothelial cells. Interestingly, intestinal epithelial cells only express TLR4 at low levels and this may explain why these cells are reasonably tolerant to LPS, possibly to prevent a full-blown immune response that could easily be triggered by the presence of a large number of colonizing bacteria in the intestinal lumen [30]. TLR4 mediates lipopolysaccharide-induced maturation and activation of myeloid dendritic cells and TLR4 upregulation in colonic mucosal epithelium and myeloid dendritic cells is observed in patients with active IBD [16]. The association of IBD with genetic variants in the TLR4 gene has been previously reported but the results are contradictory, which may be explained by genetic heterogeneity between populations, stratification bias, or small sample size [15, 42]. Meena et al. reported that TLR4 rs4986790A>G polymorphism is also associated with inflammatory bowel disease in North Indian population and further demonstrated its role in modulating the expression of inflammatory cytokines, leading to aberrant immune response in UC [28]. Collectively, these results discussed above suggest that TLR4 rs4986790A>G and rs4986791C>T polymorphisms confer increased susceptibility to IBD.

It is clear from the discussion above that ethnic differences may potentially influence the impact of TLR4 rs4986790A>G and rs4986791C>T polymorphisms on IBD progression. Subgroup analyses based on ethnicity and IBD disease type were performed to identify such differences. Our ethnicity-stratified analysis demonstrated that TLR4 rs4986790A>G and rs4986791C>T polymorphisms were associated with an elevated susceptibility to IBDs in both Asian and Caucasian populations. Subgroup analysis based on IBD disease type suggested that rs4986790A>G polymorphism increases the risk of both UC and CD. Interestingly, our findings showed that TLR4 rs4986791C>T polymorphism may increase the susceptibility to UC but did not influence the risk of CD.

Limitations of our study should be noted while interpreting the result of our meta-analysis. First, our lack of access to the original data from the included studies limited a detailed assessment of potential interacting factors. Second, in the current meta-analysis the majority of the 13 eligible studies were performed in Caucasians and Asians, which may lead to bias. Moreover, studies published in languages other than English were also not included in our meta-analysis and, therefore, potentially relevant studies that could have influenced the results of this study may have been missed.

In conclusion, TLR4 SNPs, rs4986790A>G and rs4986791C>T, are intimately associated with increased risk of IBD. Although the specific role of these polymorphisms in the etiopathogenesis of IBD and its two disease types remains elusive, it is possible that future studies may reveal the molecular mechanisms of IBD through experimental studies focused on these polymorphisms.

Acknowledgment

The authors would like to acknowledge the reviewers for their helpful comments on this paper.

Conflict of Interests

The authors have declared that no competing interests exist.

References

  • 1.Pedersen N., Duricova D., Elkjaer M., Gamborg M., Munkholm P., Jess T. Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies. The American Journal of Gastroenterology. 2010;105(7):1480–1487. doi: 10.1038/ajg.2009.760. [DOI] [PubMed] [Google Scholar]
  • 2.Lehtinen P., Ashorn M., Iltanen S., et al. Incidence trends of pediatric inflammatory bowel disease in Finland, 1987–2003, a nationwide study. Inflammatory Bowel Diseases. 2011;17(8):1778–1783. doi: 10.1002/ibd.21550. [DOI] [PubMed] [Google Scholar]
  • 3.Anderson C. A., Boucher G., Lees C. W., et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nature Genetics. 2011;43(3):246–252. doi: 10.1038/ng.764. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Dudarewicz M., Barańska M., Rychlik-Sych M., Trzciński R., Dziki A., Skreţkowicz J. C3435T polymorphism of the ABCB1/MDR1 gene encoding P-glycoprotein in patients with inflammatory bowel disease in a Polish population. Pharmacological Reports. 2012;64(2):343–350. doi: 10.1016/s1734-1140(12)70774-0. [DOI] [PubMed] [Google Scholar]
  • 5.Frank D. N., Robertson C. E., Hamm C. M., et al. Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases. Inflammatory Bowel Diseases. 2011;17(1):179–184. doi: 10.1002/ibd.21339. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Verma R., Verma A. K., Ahuja V., Paul J. Real-time analysis of mucosal flora in patients with inflammatory bowel disease in India. Journal of Clinical Microbiology. 2010;48(11):4279–4282. doi: 10.1128/jcm.01360-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Lévêque N., Brixi-Benmansour H., Reig T., et al. Low frequency of cytomegalovirus infection during exacerbations of inflammatory bowel diseases. Journal of Medical Virology. 2010;82(10):1694–1700. doi: 10.1002/jmv.21877. [DOI] [PubMed] [Google Scholar]
  • 8.Cabré E., Domènech E. Impact of environmental and dietary factors on the course of inflammatory bowel disease. World Journal of Gastroenterology. 2012;18(29):3814–3822. doi: 10.3748/wjg.v18.i29.3814. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Stronati L., Negroni A., Pierdomenico M., et al. Altered expression of innate immunity genes in different intestinal sites of children with ulcerative colitis. Digestive and Liver Disease. 2010;42(12):848–853. doi: 10.1016/j.dld.2010.04.003. [DOI] [PubMed] [Google Scholar]
  • 10.Sivaram G., Tiwari S. K., Bardia A., et al. Macrophage migration inhibitory factor, Toll-like receptor 4, and CD14 polymorphisms with altered expression levels in patients with ulcerative colitis. Human Immunology. 2012;73(2):201–205. doi: 10.1016/j.humimm.2011.12.006. [DOI] [PubMed] [Google Scholar]
  • 11.Qureshi S. T., Larivière L., Leveque G., et al. Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4) The Journal of Experimental Medicine. 1999;189(4):615–625. doi: 10.1084/jem.189.4.615. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Shen X., Shi R., Zhang H., Li K., Zhao Y., Zhang R. The toll-like receptor 4 D299G and T399I polymorphisms are associated with crohn's disease and ulcerative colitis: a meta-analysis. Digestion. 2010;81(2):69–77. doi: 10.1159/000260417. [DOI] [PubMed] [Google Scholar]
  • 13.Takeuchi O., Matsushita K., Akira S. Control of inflammatory responses by a novel RNase, Zc3h12a. Tanpakushitsu Kakusan Koso. 2009;54(14):1837–1841. [PubMed] [Google Scholar]
  • 14.Tang H., Pang S., Wang M., et al. TLR4 activation is required for IL-17-induced multiple tissue inflammation and wasting in mice. The Journal of Immunology. 2010;185(4):2563–2569. doi: 10.4049/jimmunol.0903664. [DOI] [PubMed] [Google Scholar]
  • 15.Mohammadi M., Zahedi M. J., Nikpoor A. R., Baneshi M. R., Hayatbakhsh M. M. Interleukin-17 serum levels and TLR4 polymorphisms in ulcerative colitis. Iranian Journal of Immunology. 2013;10(2):83–92. [PubMed] [Google Scholar]
  • 16.Baumgart D. C., Büning C., Geerdts L., et al. The c.1-260C>T promoter variant of CD14 but not the c.896A>G (p.D299G) variant of toll-like receptor 4 (TLR4) genes is associated with inflammatory bowel disease. Digestion. 2007;76(3-4):196–202. doi: 10.1159/000112646. [DOI] [PubMed] [Google Scholar]
  • 17.Ioana M., Ferwerda B., Farjadian S., et al. High variability of TLR4 gene in different ethnic groups in Iran. Innate Immunity. 2012;18(3):492–502. doi: 10.1177/1753425911423043. [DOI] [PubMed] [Google Scholar]
  • 18.Shen X.-Y., Shi R.-H., Wang Y., et al. Toll-like receptor gene polymorphisms and susceptibility to inflammatory bowel disease in Chinese Han and Caucasian populations. Zhonghua Yi Xue Za Zhi. 2010;90(20):1416–1420. [PubMed] [Google Scholar]
  • 19.Chen H., Manning A. K., Dupuis J. A method of moments estimator for random effect multivariate meta-analysis. Biometrics. 2012;68(4):1278–1284. doi: 10.1111/j.1541-0420.2012.01761.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Peters J. L., Sutton A. J., Jones D. R., Abrams K. R., Rushton L. Comparison of two methods to detect publication bias in meta-analysis. Journal of the American Medical Association. 2006;295(6):676–680. doi: 10.1001/jama.295.6.676. [DOI] [PubMed] [Google Scholar]
  • 21.Zintzaras E., Ioannidis J. P. A. Heterogeneity testing in meta-analysis of genome searches. Genetic Epidemiology. 2005;28(2):123–137. doi: 10.1002/gepi.20048. [DOI] [PubMed] [Google Scholar]
  • 22.Huizenga H. M., Visser I., Dolan C. V. Testing overall and moderator effects in random effects meta-regression. British Journal of Mathematical and Statistical Psychology. 2011;64(1):1–19. doi: 10.1348/000711010x522687. [DOI] [PubMed] [Google Scholar]
  • 23.Jackson D., White I. R., Riley R. D. Quantifying the impact of between-study heterogeneity in multivariate meta-analyses. Statistics in Medicine. 2012;31(29):3805–3820. doi: 10.1002/sim.5453. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Ferrenberg A. M., Swendsen R. H. New Monte Carlo technique for studying phase transitions. Physical Review Letters. 1988;61(23):2635–2638. doi: 10.1103/physrevlett.61.2635. [DOI] [PubMed] [Google Scholar]
  • 25.Sterne J. A. C., Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. Journal of Clinical Epidemiology. 2001;54(10):1046–1055. doi: 10.1016/s0895-4356(01)00377-8. [DOI] [PubMed] [Google Scholar]
  • 26.Wikstrom E. A., Naik S., Lodha N., Cauraugh J. H. Balance capabilities after lateral ankle trauma and intervention: a meta-analysis. Medicine and Science in Sports and Exercise. 2009;41(6):1287–1295. doi: 10.1249/mss.0b013e318196cbc6. [DOI] [PubMed] [Google Scholar]
  • 27.Egger M., Smith G. D., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. British Medical Journal. 1997;315(7109):629–634. doi: 10.1136/bmj.315.7109.629. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Meena N. K., Verma R., Verma N., Ahuja V., Paul J. TLR4 D299G polymorphism modulates cytokine expression in ulcerative colitis. Journal of Clinical Gastroenterology. 2013;47(9):773–780. doi: 10.1097/MCG.0b013e31828a6e93. [DOI] [PubMed] [Google Scholar]
  • 29.Magalhäes Queiroz D. M., Gonçalves Oliveira A., Saraiva I. E. B., et al. Immune response and gene polymorphism profiles in Crohn's disease and ulcerative colitis. Inflammatory Bowel Diseases. 2009;15(3):353–358. doi: 10.1002/ibd.20757. [DOI] [PubMed] [Google Scholar]
  • 30.Rigoli L., Romano C., Caruso R. A., et al. Clinical significance of NOD2/CARD15 and Toll-like receptor 4 gene single nucleotide polymorphisms in inflammatory bowel disease. World Journal of Gastroenterology. 2008;14(28):4454–4461. doi: 10.3748/wjg.14.4454. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Lappalainen M., Halme L., Turunen U., et al. Association of IL23R, TNFRSF1A, and HLA-DRB1∗0103 allele variants with inflammatory bowel disease phenotypes in the Finnish population. Inflammatory Bowel Diseases. 2008;14(8):1118–1124. doi: 10.1002/ibd.20431. [DOI] [PubMed] [Google Scholar]
  • 32.Hong J., Leung E., Fraser A. G., Merriman T. R., Vishnu P., Krissansen G. W. TLR2, TLR4 and TLR9 polymorphisms and Crohn's disease in a New Zealand Caucasian cohort. Journal of Gastroenterology and Hepatology. 2007;22(11):1760–1766. doi: 10.1111/j.1440-1746.2006.04727.x. [DOI] [PubMed] [Google Scholar]
  • 33.Browning B. L., Huebner C., Petermann I., et al. Has toll-like receptor 4 been prematurely dismissed as an inflammatory bowel disease gene? Association study combined with meta-analysis shows strong evidence for association. The American Journal of Gastroenterology. 2007;102(11):2504–2512. doi: 10.1111/j.1572-0241.2007.01463.x. [DOI] [PubMed] [Google Scholar]
  • 34.Oostenbrug L. E., Drenth J. P. H., de Jong D. J., et al. Association between Toll-like receptor 4 and inflammatory bowel disease. Inflammatory Bowel Diseases. 2005;11(6):567–575. doi: 10.1097/01.mib.0000161305.81198.0f. [DOI] [PubMed] [Google Scholar]
  • 35.Brand S., Staudinger T., Schnitzler F., et al. The role of Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms and CARD15/NOD2 mutations in the susceptibility and phenotype of Crohn's disease. Inflammatory Bowel Diseases. 2005;11(7):645–652. doi: 10.1097/01.mib.0000168372.94907.d2. [DOI] [PubMed] [Google Scholar]
  • 36.Török H.-P., Glas J., Tonenchi L., Mussack T., Folwaczny C. Polymorphisms of the lipopolysaccharide-signaling complex in inflammatory bowel disease: association of a mutation in the Toll-like receptor 4 gene with ulcerative colitis. Clinical Immunology. 2004;112(1):85–91. doi: 10.1016/j.clim.2004.03.002. [DOI] [PubMed] [Google Scholar]
  • 37.Franchimont D., Vermeire S., El Housni H., et al. Deficient host-bacteria interactions in inflammatory bowel disease? the toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut. 2004;53(7):987–992. doi: 10.1136/gut.2003.030205. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Gay N. J., Gangloff M. Structure and function of toll receptors and their ligands. Annual Review of Biochemistry. 2007;76:141–145. doi: 10.1146/annurev.biochem.76.060305.151318. [DOI] [PubMed] [Google Scholar]
  • 39.Kutikhin A. G. Impact of Toll-like receptor 4 polymorphisms on risk of cancer. Human Immunology. 2011;72(2):193–206. doi: 10.1016/j.humimm.2010.11.003. [DOI] [PubMed] [Google Scholar]
  • 40.Sawian C. E., Lourembam S. D., Banerjee A., Baruah S. Polymorphisms and expression of TLR4 and 9 in malaria in two ethnic groups of Assam, northeast India. Innate Immunity. 2013;19(2):174–183. doi: 10.1177/1753425912455675. [DOI] [PubMed] [Google Scholar]
  • 41.Kim H. M., Park B. S., Kim J.-I., et al. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell. 2007;130(5):906–917. doi: 10.1016/j.cell.2007.08.002. [DOI] [PubMed] [Google Scholar]
  • 42.Rioux J. D., Xavier R. J., Taylor K. D., et al. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nature Genetics. 2007;39(5):596–604. doi: 10.1038/ng2032. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Gastroenterology Research and Practice are provided here courtesy of Wiley

RESOURCES